Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy
Jesus G. Berdeja; Todd Bauer; Edward Arrowsmith; James Essell; Patrick Murphy; James A. Reeves; Ralph V. Boccia; William Donnellan; Ian Flinn
Author Information: Sarah Cannon Research Institute
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.